Dr. Xuan Zhou 周旋
Chief Physician
Department of Head and Neck Oncology (Thyroid, Maxillofacial, and Otolaryngology), Tianjin Medical University Cancer Institute & Hospital, Tianjin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical treatment of thyroid, parotid, submandibular, laryngeal, hypopharyngeal, and oral-maxillofacial tumors. Expertise includes function-preserving thyroidectomy, laryngeal cancer surgery, free flap reconstruction for oral cancer, and hypopharyngeal reconstruction using tubular stomach formation.
Dr. Zhou is a Chief Physician, Professor, and Doctoral Supervisor at Tianjin Medical University Cancer Institute & Hospital, serving as Deputy Director of the Head and Neck Oncology Department. Dr. Zhou was a visiting scholar at the Head and Neck Surgery Center of UTMDACC in the United States.
Professional roles
- Standing Committee Member, Youth Council, China Anti-Cancer Association
- Standing Committee Member, Integrated Rehabilitation Committee for Oral and Maxillofacial Tumors, China Anti-Cancer Association
- Standing Committee Member, Integrated Prevention and Screening Committee for Oral Cancer, China Anti-Cancer Association
- Vice Chair, Head and Neck Oncology Committee, Tianjin Anti-Cancer Association
Name order: in Chinese the family name comes first (Zhou Xuan). Papers usually list the name as Xuan Zhou or Zhou X.
Selected publications
64 papers on PubMed matched by name and affiliation; 24 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Nanobiotechnology, 2025 (senior author): Reprogramming tumor-associated macrophages and blocking PD-L1 via engineered outer membrane vesicles to enhance T cell infiltration and cytotoxic functions. PubMed 40660251
- Int J Oncol, 2025 (senior author): [Retracted] Role of the EZH2/miR‑200 axis in STAT3‑mediated OSCC invasion. PubMed 40116088
- Cancer Lett, 2025 (senior author): Osteopontin promotes tumor microenvironment remodeling and therapy resistance. PubMed 40058726
- Cancer Lett, 2024 (senior author): Targeting STAT3 potentiates CDK4/6 inhibitors therapy in head and neck squamous cell carcinoma. PubMed 38735381
- Cancer Lett, 2024 (senior author): Targeting IL-6/STAT3 signaling abrogates EGFR-TKI resistance through inhibiting Beclin-1 dependent autophagy in HNSCC. PubMed 38211653
- Int J Oncol, 2023 (senior author): [Corrigendum] Role of the EZH2/miR‑200 axis in STAT3‑mediated OSCC invasion. PubMed 37264965
- Front Oncol, 2023 (senior author): The role of BHLHE40 in clinical features and prognosis value of PDAC by comprehensive analysis and in vitro validation. PubMed 37377917
- Br J Cancer, 2023 (senior author): Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy. PubMed 36522474
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion